Abstract
Drug resistance is a problem in many pathogens, including viruses, bacteria, fungi and parasites [1]. While overall, levels of resistance have risen in recent decades, there are many examples where after an initial rise, levels of resistance have stabilized [2–6]. The stable coexistence of resistance and susceptibility has proven hard to explain – in most evolutionary models, either resistance or susceptibility ultimately “wins” and takes over the population [2,3,7–9]. Here, we show that a simple stochastic model, mathematically akin to mutation-selection balance theory, can explain several key observations about drug resistance: (1) the stable coexistence of resistant and susceptible strains (2) at levels that depend on population-level drug usage and (3) with resistance often due to many different strains (resistance is present on many different genetic backgrounds). The model works for resistance due to both mutations or horizontal gene transfer (HGT). It predicts that new resistant strains should continuously appear (through mutation or HGT and positive selection within treated hosts) and disappear (due to the cost of resistance). The result is that while resistance is stable, which strains carry resistance is constantly changing. We used data on 37,000 E. coli isolates to test this prediction for a known resistance mutation and a resistance gene in the UK and found that the data are consistent with the prediction. Having a model that explains the dynamics of drug resistance will allow us to plan science-backed interventions to reduce the burden of drug resistance. Next, it will be of interest to test our model on data from different drug-pathogen combinations and to estimate model parameters for these drug–pathogen combinations in different geographic regions with varying levels of drug use. It will then be possible to predict the results of interventions, especially drug restriction policies and increase our understanding of whether and how fast such restrictions should result in reduced resistance [10,11].
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data and code are on github: https://github.com/pleunipennings/CoexistencePaper
